Asunto(s)
Infecciones por Virus de Epstein-Barr/complicaciones , Infecciones por Virus de Epstein-Barr/diagnóstico , Eritema Nudoso/virología , Enfermedad Crónica , Infecciones por Virus de Epstein-Barr/patología , Femenino , Hepatomegalia/virología , Humanos , Esplenomegalia/virología , Carga Viral , Adulto JovenAsunto(s)
Antígenos Virales/sangre , Antivirales/administración & dosificación , Infecciones por Citomegalovirus/prevención & control , Ganciclovir/administración & dosificación , Pénfigo/terapia , Anciano , Profilaxis Antibiótica/métodos , Antígenos Virales/inmunología , Citomegalovirus/inmunología , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/inmunología , Infecciones por Citomegalovirus/virología , Relación Dosis-Respuesta a Droga , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Humanos , Huésped Inmunocomprometido , Inmunosupresores/administración & dosificación , Inmunosupresores/efectos adversos , Inmunoterapia/efectos adversos , Inmunoterapia/métodos , Masculino , Pénfigo/sangre , Pénfigo/inmunología , Plasmaféresis/efectos adversos , Resultado del TratamientoAsunto(s)
Nervio Glosofaríngeo , Herpes Zóster/complicaciones , Herpesvirus Humano 3/aislamiento & purificación , Nervio Laríngeo Recurrente , Parálisis de los Pliegues Vocales/etiología , Aciclovir/uso terapéutico , Antivirales/uso terapéutico , Pabellón Auricular , Femenino , Herpes Zóster/diagnóstico , Herpes Zóster/tratamiento farmacológico , Herpes Zóster/virología , Humanos , Músculos Laríngeos/inervación , Metilprednisolona/administración & dosificación , Persona de Mediana Edad , Paresia/etiología , Paresia/prevención & control , Quimioterapia por Pulso , Piel/virología , Resultado del TratamientoAsunto(s)
Trasplante de Células Madre Hematopoyéticas/efectos adversos , Mucopolisacaridosis II/terapia , Urticaria/patología , Vasculitis/patología , Biopsia , Niño , Extremidades , Glicosaminoglicanos/metabolismo , Humanos , Masculino , Microscopía Electrónica , Remisión Espontánea , Piel/patología , Tejido Subcutáneo/patología , Tejido Subcutáneo/ultraestructura , Urticaria/diagnóstico , Urticaria/etiología , Vasculitis/diagnóstico , Vasculitis/etiologíaAsunto(s)
Dermatosis del Pie/patología , Penfigoide Ampolloso/patología , Anciano de 80 o más Años , Antiinflamatorios/uso terapéutico , Autoanticuerpos/sangre , Autoantígenos/inmunología , Femenino , Dermatosis del Pie/tratamiento farmacológico , Humanos , Colágenos no Fibrilares/inmunología , Penfigoide Ampolloso/tratamiento farmacológico , Prednisolona/uso terapéutico , Colágeno Tipo XVIIAsunto(s)
Bortezomib/efectos adversos , Infecciones por Citomegalovirus/inmunología , Herpes Zóster/inmunología , Mieloma Múltiple/tratamiento farmacológico , Activación Viral/efectos de los fármacos , Anciano , Biopsia , Bortezomib/administración & dosificación , Citomegalovirus/aislamiento & purificación , Citomegalovirus/fisiología , Infecciones por Citomegalovirus/patología , Infecciones por Citomegalovirus/virología , Dexametasona/administración & dosificación , Herpes Zóster/patología , Herpes Zóster/virología , Herpesvirus Humano 3/aislamiento & purificación , Herpesvirus Humano 3/fisiología , Humanos , Huésped Inmunocomprometido , Pierna , Masculino , Mieloma Múltiple/inmunología , Piel/inmunología , Piel/patología , Piel/virología , Activación Viral/inmunologíaRESUMEN
BACKGROUND & AIMS: Recently, we conducted a prospective randomized controlled trial (RCT) showing that a 6-month 130g/day low-carbohydrate diet (LCD) reduced HbA1c and BMI more than a calorie restricted diet (CRD). [1] To assess whether the benefits of the LCD persisted after the intensive intervention, we compared HbA1c and BMI between the LCD and CRD groups at 1 year after the end of the 6-month RCT. METHODS: Following the end of the 6-month RCT, patients were allowed to manage their own diets with periodic outpatient visits. One year later, we analyzed clinical and nutrition data. RESULTS: Of the 66 participants in the original study, 27 in the CRD group and 22 in the LCD group completed this trial. One year after the end of the original RCT, the carbohydrate intake was comparable between the groups (215 [189-243]/day in the CRD group and 214 (176-262) g/day in the LCD group). Compared with the baseline data, HbA1c and BMI were decreased in both groups (CRD: HbA1c -0.4 [-0.9 to 0.3] % and BMI -0.63 [-1.20 to 0.18] kg/m2; LCD: HbA1c -0.35 [-1.0 to 0.35] % and BMI -0.77 [-1.15 to -0.12] kg/m2). There were no significant differences in HbA1c and BMI between the groups. CONCLUSIONS: One year after the diet therapy intervention, the beneficial effect of the LCD on reduction of HbA1c and BMI did not persist in comparison with CRD. However, combining the data of both groups, significant improvements in HbA1c and BMI from baseline were observed. Although the superiority of the LCD disappeared 1 year after the intensive intervention, these data suggest that well-constructed nutrition therapy programs, both CRD and LCD, were equally effective in improving HbA1c for at least 1 year. TRIAL REGISTRATION: University Hospital Medical Information Network (UMIN) ID000010663.
Asunto(s)
Glucemia/análisis , Diabetes Mellitus Tipo 2/dietoterapia , Carbohidratos de la Dieta/administración & dosificación , Anciano , Diabetes Mellitus Tipo 2/sangre , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Antineoplásicos/efectos adversos , Carcinoma de Células Renales/tratamiento farmacológico , Neoplasias Renales/tratamiento farmacológico , Úlcera de la Pierna/inducido químicamente , Pirimidinas/efectos adversos , Sulfonamidas/efectos adversos , Anciano , Humanos , Indazoles , Úlcera de la Pierna/patología , Masculino , Niacinamida/efectos adversos , Niacinamida/análogos & derivados , Compuestos de Fenilurea/efectos adversos , Inhibidores de Proteínas Quinasas/efectos adversos , SorafenibAsunto(s)
Eosinofilia/patología , Eritema/patología , Cuello/patología , Enfermedades Cutáneas Genéticas/patología , Anciano , Eosinofilia/tratamiento farmacológico , Eritema/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Humanos , Masculino , Prednisolona/uso terapéutico , Enfermedades Cutáneas Genéticas/tratamiento farmacológicoRESUMEN
BACKGROUND & AIMS: The usefulness of low-carbohydrate diet (LCD) for Japanese patients with type 2 diabetes mellitus (T2DM) has not been fully investigated. Therefore, we compared the effectiveness and safety of LCD with calorie restricted diet (CRD). METHODS: This prospective, randomized, open-label, comparative study included 66 T2DM patients with HbA1c >7.5% even after receiving repeated education programs on CRD. They were randomly allocated to either the 130g/day LCD group (n = 33) or CRD group (n = 33). Patients received personal nutrition education of CRD or LCD for 30 min at baseline, 1, 2, 4, and 6 months. Patients of the CRD group were advised to maintain the intake of calories and balance of macronutrients (28× ideal body weight calories per day). Patients of the LCD group were advised to maintain the intake of 130 g/day carbohydrate without other specific restrictions. Several parameters were assessed at baseline and 6 months after each intervention. The primary endpoint was a change in HbA1c level from baseline to the end of the study. RESULTS: At baseline, BMI and HbA1c were 26.5 (24.6-30.1) and 8.3 (8.0-9.3), and 26.7 (25.0-30.0) kg/m2 and 8.0 (7.6-8.9) %, in the CRD and LCD, respectively. At the end of the study, HbA1c decreased by -0.65 (-1.53 to -0.10) % in the LCD group, compared with 0.00 (-0.68 to 0.40) % in the CRD group (p < 0.01). Also, the decrease in BMI in the LCD group [-0.58 (-1.51 to -0.16) kg/m2] exceeded that observed in the CRD group (p = 0.03). CONCLUSIONS: Our study demonstrated that 6-month 130 g/day LCD reduced HbA1c and BMI in poorly controlled Japanese patients with T2DM. LCD is a potentially useful nutrition therapy for Japanese patients who cannot adhere to CRD. This trial was registered at http://www.umin.ac.jp/english/ (University Hospital Medical Information Network: study ID number 000010663).
Asunto(s)
Diabetes Mellitus Tipo 2/dietoterapia , Dieta Baja en Carbohidratos , Dieta para Diabéticos , Hiperglucemia/prevención & control , Hipoglucemia/prevención & control , Cooperación del Paciente , Medicina de Precisión , Anciano , Índice de Masa Corporal , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/etnología , Dieta Baja en Carbohidratos/etnología , Dieta para Diabéticos/etnología , Dieta Reductora/etnología , Ingestión de Energía/etnología , Femenino , Estudios de Seguimiento , Hemoglobina Glucada/análisis , Humanos , Japón , Masculino , Persona de Mediana Edad , Ciencias de la Nutrición/educación , Sobrepeso/sangre , Sobrepeso/complicaciones , Sobrepeso/dietoterapia , Sobrepeso/etnología , Cooperación del Paciente/etnología , Educación del Paciente como Asunto , Pérdida de Peso/etnologíaRESUMEN
Juvenile hormones (JHs) of insects are sesquiterpenoids that regulate a great diversity of processes in development and reproduction. As yet the molecular modes of action of JH are poorly understood. The Methoprene-tolerant (Met) gene of Drosophila melanogaster has been found to be responsible for resistance to a JH analogue (JHA) insecticide, methoprene. Previous studies on Met have implicated its involvement in JH signaling, although direct evidence is lacking. We have now examined the product of Met (MET) in terms of its binding to JH and ligand-dependent gene regulation. In vitro synthesized MET directly bound to JH III with high affinity (Kd = 5.3 +/- 1.5 nm, mean +/- SD), consistent with the physiological JH concentration. In transient transfection assays using Drosophila S2 cells the yeast GAL4-DNA binding domain fused to MET exerted JH- or JHA-dependent activation of a reporter gene. Activation of the reporter gene was highly JH- or JHA-specific with the order of effectiveness: JH III >> JH II > JH I > methoprene; compounds which are only structurally related to JH or JHA did not induce any activation. Localization of MET in the S2 cells was nuclear irrespective of the presence or absence of JH. These results suggest that MET may function as a JH-dependent transcription factor.